SCHEMBL25569655

SCHEMBL25569655

CCNC(CC)C(=O)c1ccc2c(c1)CCS2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MAPT P10636 5/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
LMNA P02545 3/20 0.33
TAS1R3 Q7RTX0 2/20 0.33
TAS1R1 Q7RTX1 2/20 0.33
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 1/20 0.33
SLC6A4 P31645 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ALOX15 P16050 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A3 Q01959 1/20 0.32
GAA P10253 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24197470 0.90 MAPT (0.33) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL25569656 0.88 HDAC1 (0.34) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL25569647 0.86 MAPT (0.35) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL25569463 0.81 KDM4E (0.33) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL25569789 0.80 MAPT (0.35) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL25569464 0.80 KDM4E (0.32) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL25569465 0.80 LMNA (0.32) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL24197468 0.78 MAPT (0.34) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL25569649 0.76 HTR1B (0.45) HDAC1HDAC8HDAC6MAPTKDM4E
SCHEMBL24197474 0.75 CHRNA1 (0.34) HDAC1HDAC8HDAC6MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159487-A1 ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT SLC6A3, CREBBP, SLC1A2 HDAC1 1235/4885HDAC8 1976/4885HDAC6 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.